Nasus Pharma NS002 Clinical Trial Shows Positive Interim Results
Nasus Pharma announced positive interim results from its Phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The data demonstrated that NS002 achieved faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to intramuscular EpiPen autoinjector. NS002 demonstrated a higher mean peak plasma concentration of 655 pg/ml compared to 548 pg/ml for EpiPen, and achieved peak concentration in 10.8 minutes compared to 15 minutes with EpiPen. 91% of participants administered NS002 reached the epinephrine plasma threshold of 100 pg/ml at 5 minutes, compared to 67% of those administered EpiPen. Total epinephrine absorption in the 10 minute period following administration-the critical window for resolving anaphylaxis-was higher in participants administered NS002 compared to EpiPen.
Trade with 70% Backtested Accuracy
Analyst Views on NSRX
About NSRX
About the author
Nasus Pharma Secures $15 Million in Private Placement Financing
- Financing Size: Nasus Pharma has entered into a securities purchase agreement for a private placement of $15 million, expected to close on February 12, 2026, with proceeds aimed at advancing the clinical development of NS002 and other pipeline products.
- Share Issuance Details: The private placement will issue 2,695,425 ordinary shares and the same number of warrants, priced at $5.565 per share, with warrants exercisable at $6.53, reflecting investor confidence in the company's growth potential.
- Market Reaction: The placement price exceeds Nasus Pharma's recent closing price, indicating a positive outlook from investors regarding the company's future market performance, which may have a favorable impact on its stock price.
- Strategic Use: The company intends to use the net proceeds to advance pivotal clinical studies for NS002, initiate first-in-human trials for other products, and for general corporate purposes, demonstrating its ongoing commitment to innovative drug development.
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
Nasus Pharma Enhances Leadership by Appointing Eyal Rubin as Executive Vice President and CFO
New Executive Appointment: Nasus Pharma has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical sectors.
Role and Responsibilities: Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company progresses its intranasal therapeutics pipeline.
Company's Focus: Nasus Pharma is developing innovative intranasal products, including a needle-free alternative to Epinephrine autoinjectors for anaphylaxis, utilizing proprietary powder-based intranasal technology for rapid drug delivery.
Leadership Confidence: The company's leadership expresses confidence in Mr. Rubin's expertise to enhance financial and operational capabilities, supporting the advancement of clinical programs and long-term growth.
Nasus Pharma Secures $15 Million in Private Placement Financing
- Financing Size: Nasus Pharma has entered into a securities purchase agreement for a private placement of $15 million, expected to close on February 12, 2026, with proceeds aimed at advancing the clinical development of NS002 and other pipeline products.
- Share Issuance Details: The private placement will issue 2,695,425 ordinary shares and the same number of warrants, priced at $5.565 per share, with warrants exercisable at $6.53, reflecting investor confidence in the company's growth potential.
- Market Reaction: The placement price exceeds Nasus Pharma's recent closing price, indicating a positive outlook from investors regarding the company's future market performance, which may have a favorable impact on its stock price.
- Strategic Use: The company intends to use the net proceeds to advance pivotal clinical studies for NS002, initiate first-in-human trials for other products, and for general corporate purposes, demonstrating its ongoing commitment to innovative drug development.
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
Nasus Pharma Enhances Leadership by Appointing Eyal Rubin as Executive Vice President and CFO
New Executive Appointment: Nasus Pharma has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical sectors.
Role and Responsibilities: Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company progresses its intranasal therapeutics pipeline.
Company's Focus: Nasus Pharma is developing innovative intranasal products, including a needle-free alternative to Epinephrine autoinjectors for anaphylaxis, utilizing proprietary powder-based intranasal technology for rapid drug delivery.
Leadership Confidence: The company's leadership expresses confidence in Mr. Rubin's expertise to enhance financial and operational capabilities, supporting the advancement of clinical programs and long-term growth.
